In order to grow, invade and metastasise, a tumour must recruit and maintain a vascular infrastructure through the process of angiogenesis. Traditionally, anti-cancer therapy has targeted cancer cells themselves with relatively nonspeci®c cytotoxic agents, but newer approaches to treatment have included tumour angiogenesis as a target for therapeutic intervention. In our laboratory, we have developed an adenoviral mediated gene therapy strategy that targets tumour cell production of factors important in the angiogenic cascade. Using an antisense adenoviral expression system, we have targeted the cellular expression of basic ®broblast growth factor (bFGF), interleukin-8 (IL-8), and vascular endothelial growth factor (VEGF) in aggressive urologic malignancies, including human prostate cancer.
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Reverse transcriptase-polymerase chain reaction using angiogenic peptide-speci®c primers was used to generate full-length cDNA clones encoding for the angiogenic factors IL-8, bFGF, and VEGF. These were then directionally cloned in an antisense orientation into the shuttle vector pCA14 and co-transfected with pJM-17 into 293 cells to generate recombinant replication de®cient adenovirus. Viral titres, multiplicity of infection and viral cytotoxicity were then determined for each antisense viral vector, after ampli®cation in 293 cells. We then used the prostate cancer cell lines PC3-LN4 and LNCaP-LN3 to test the effects of these antisense viruses in vitro and in vivo. PC3-LN4 is an aggressive tumourigenic and metastatic prostate cancer subline of PC-3 that produces signi®cantly increased levels of both IL-8 and bFGF as compared to parental. We used these prostate cancer sublines to study the effects of adenoviral infection on angiogenic factor expression, in vivo tumourigenicity, and on the expression of factors important in prostate cancer cell invasion, metastasis, cell cycle regulation, and apoptosis.
Antisense adenoviral gene therapy targeting bFGF, IL-8, or VEGF resulted in an 80 ± 90% reduction in tumour cell production of each targeted angiogenic factor, based on ELISA analysis, with minimal viral mediated cytotoxicity. The duration of antisense gene expression was approximately 11 ± 14 days following a single infection, based on Northern analysis of total cellular RNA. Antisense viral infection did not alter the in vitro growth kinetics of the cell lines, despite downregulation of angiogenic factor expression. Targeted downregulation of one angiogenic factor following adenoviral infection had no effect on the expression of the other angiogenic factors by the tumour cells. Adenoviral infection with the different antisense vectors signi®cantly inhibited tumourigenicity and metastasis in a nude mouse model of human prostate cancer. Antisense adenoviral gene therapy of existing tumours in the¯anks of nude animals resulted in signi®cant reduction in tumour size with a downregulation in markers of angiogenesis, including microvessel density. Adenoviral mediated downregulation of 1L-8, bFGF, or VEGF also signi®cantly decreased expression of matrix metalloproteinase (MMP)-2, MMP-9, urokinase plasminogen activator receptor and bcl-2, while increasing the expression of BAX, p21, and p27 in tumour cells.
Adenoviral mediated antisense gene therapy targeting human prostate cancer angiogenic factor production represents a novel approach to therapy for aggressive prostate cancer. The reduction in angiogenic factor expression, mediated through antisense adenoviral gene therapy, was associated with a signi®cant reduction in both angiogenic factor expression as well as signi®cant alterations in the expression of markers of prostate cancer virulence.
